• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by Accolade Inc.

    4/10/25 9:03:06 AM ET
    $ACCD
    Business Services
    Consumer Discretionary
    Get the next $ACCD alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)


    ACCOLADE, INC.

    (Name of Issuer)


    Common Stock, par value $.0001

    (Title of Class of Securities)


    00437E102

    (CUSIP Number)


    David J. Snyderman
    1603 Orrington Avenue, 13th Floor
    Evanston, IL, 60201
    847-905-4400

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    04/08/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    00437E102


    1 Name of reporting person

    Magnetar Financial LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    IA, OO



    SCHEDULE 13D

    CUSIP No.
    00437E102


    1 Name of reporting person

    Magnetar Capital Partners LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    HC, OO



    SCHEDULE 13D

    CUSIP No.
    00437E102


    1 Name of reporting person

    Supernova Management LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    HC, OO



    SCHEDULE 13D

    CUSIP No.
    00437E102


    1 Name of reporting person

    David J. Snyderman
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    IN, HC



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $.0001
    (b)Name of Issuer:

    ACCOLADE, INC.
    (c)Address of Issuer's Principal Executive Offices:

    1201 Third Avenue, Suite 1700, Seattle, WASHINGTON , 98101.
    Item 2.Identity and Background
    (a)
    This Amendment No. 1 ("Amendment No. 1") relates to the Statement of Beneficial Ownership on Schedule 13D filed jointly by Magnetar Financial LLC, a Delaware limited liability company ("Magnetar Financial"), Magnetar Capital Partners LP, a Delaware limited partnership ("Magnetar Capital Partners"), Supernova Management LLC, a Delaware limited liability company ("Supernova Management"), and David J. Snyderman ("Mr. Snyderman") with the SEC on April 10, 2025, (as amended by this Amendment No. 1, the "Schedule 13D"). This Amendment No. 1 is being filed to report that the Reporting Persons are no longer beneficial owners of more than 5% of the Shares. The filing of this Amendment No. 1 represents the final amendment to this Schedule 13D and constitutes an exit filing for the Reporting Persons. Except as set forth below, all Items of the Schedule 13D remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D.
    Item 4.Purpose of Transaction
     
    Item 4 of the Schedule 13D is hereby amended to add the following information for updating: Since the filing of Schedule 13D on January 21, 2025, on April 8, 2025 ("Effective Date"), the Issuer consummated a merger (the "Merger") pursuant to which each Share of Issuer's common stock outstanding immediately prior to the Effective Date was cancelled and converted into the right to receive $7.03 in cash, without interest. In connection with the Merger, the Reporting Persons' Shares, which consisted of 5,793,914 Shares sold for the benefit of (i) 3,482,990 Shares sold for the benefit of PRA Master Fund and (ii) 1,483,761 Shares sold for the benefit of Systematic Master Fund, and (iii) 355,329 Shares sold for the benefit of Relative Value Master Fund, and (iv) 471,834 Shares sold for the benefit of the Managed Accounts, were cancelled and converted into the right to receive $7.03 in cash, without interest.
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5(a)-(c) and (e) of the Schedule 13D is hereby amended to add the following information for updating: As of the closing of the Merger on April 8, 2025, each of the Reporting Persons may have been deemed to have beneficial ownership of 0 Shares.
    (b)
    As of the closing of the Merger on April 8, 2025, each of the Reporting Persons may have been deemed to share the power to vote and direct the disposition of 0 Shares, which represented beneficial ownership of 0% of the Shares.
    (c)
    The response to Item 4 of this Amendment No. 1 is incorporated herein by reference. The Reporting Persons purchased additional 658,243 Shares in aggregate totaling $4,550,649.50 (excluding commissions and other execution-related costs) on behalf of the Funds since the filing of the Schedule 13D on January 21, 2025.
    (d)
    As of April 8, 2025, the Reporting Persons ceased to be beneficial owners of more than five percent of the Shares.
    (e)
    N/A
    Item 7.Material to be Filed as Exhibits.
     
    99.1 Joint Filing Agreement, dated as of April 8, 2025, among the Reporting Persons. 99.2 Power of Attorney, dated as of December 22, 2022 filed by the Reporting Persons on April 8, 2025.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Magnetar Financial LLC
     
    Signature:/s/ Hayley Stein
    Name/Title:Hayley Stein/Attorney-in-fact for David J. Snyderman, Manager of Supernova Management LLC, Magnetar Capital Partners LP, its Sole Member, Supernova M
    Date:04/10/2025
     
    Magnetar Capital Partners LP
     
    Signature:/s/ Hayley Stein
    Name/Title:Hayley Stein/Attorney-in-fact for David J. Snyderman, Manager of Supernova Management LLC, Supernova Management LLC, its General Partner
    Date:04/10/2025
     
    Supernova Management LLC
     
    Signature:/s/ Hayley Stein
    Name/Title:Hayley Stein/Attorney-in-fact for David J. Snyderman, Manager of Supernova Management LLC
    Date:04/10/2025
     
    David J. Snyderman
     
    Signature:/s/ Hayley Stein
    Name/Title:Hayley Stein/Attorney-in-fact for David J. Snyderman, Manager of Supernova Management LLC
    Date:04/10/2025
    Get the next $ACCD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACCD

    DatePrice TargetRatingAnalyst
    6/28/2024$13.00 → $8.00Buy
    Needham
    2/26/2024$16.00Outperform
    Leerink Partners
    1/17/2024$16.00 → $14.00Neutral
    DA Davidson
    1/3/2024$13.00Equal Weight
    Barclays
    5/24/2023$16.50Neutral → Buy
    BofA Securities
    4/12/2023$18.00Overweight
    Stephens
    3/23/2023$16.00Neutral → Buy
    Guggenheim
    2/9/2023$14.00Buy → Hold
    Jefferies
    More analyst ratings

    $ACCD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Singh Rajeev returned $10,429,525 worth of shares to the company (1,483,574 units at $7.03), closing all direct ownership in the company (SEC Form 4)

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:52:21 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form 4 filed by Director Lepore Dawn G

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:37:34 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Director Kent Cindy returned $84,093 worth of shares to the company (11,962 units at $7.03), closing all direct ownership in the company (SEC Form 4)

    4 - Accolade, Inc. (0001481646) (Issuer)

    4/8/25 10:36:43 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham reiterated coverage on Accolade with a new price target

    Needham reiterated coverage of Accolade with a rating of Buy and set a new price target of $8.00 from $13.00 previously

    6/28/24 7:50:50 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Leerink Partners initiated coverage on Accolade with a new price target

    Leerink Partners initiated coverage of Accolade with a rating of Outperform and set a new price target of $16.00

    2/26/24 7:00:19 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    DA Davidson resumed coverage on Accolade with a new price target

    DA Davidson resumed coverage of Accolade with a rating of Neutral and set a new price target of $14.00 from $16.00 previously

    1/17/24 7:07:47 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Transcarent Completes Merger With Accolade

    Creating the Most Comprehensive Health and Care Platform for Employers and Health Plans Serving 20 Million Members & 1,700 Employer and Health Plan Clients Today Transcarent announced the successful completion of its merger with Accolade, the leading health advocacy, expert medical opinion, and virtual primary care company in the market. The combined organization now serves over 20 million Members and more than 1,700 employer and health plan clients as the One Place for Health and Care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250407811112/en/ With the completion of the transaction, Transcarent will offer a health and car

    4/8/25 9:22:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Stockholders Approve Merger Between Accolade and Transcarent

    SEATTLE, March 27, 2025 (GLOBE NEWSWIRE) -- Accolade (NASDAQ:ACCD) announced that Accolade stockholders voted to approve the merger with Transcarent at the Accolade special meeting of stockholders (the "Special Meeting") held earlier today. The final, certified voting results for the Special Meeting will be provided in a Form 8-K filed with the U.S. Securities and Exchange Commission. The transaction remains on track to be completed in the second quarter of calendar year 2025 and is subject to customary closing conditions, including the receipt of certain state regulatory approvals. Upon completion of the transaction, Accolade will become a privately held company and shares of Accol

    3/27/25 4:05:00 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Welcomes Oshi Health to Trusted Partner Ecosystem

    Partnership increases access to specialized, whole-person clinical care for people managing digestive health conditions SEATTLE, March 6, 2025 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD) has partnered with Oshi Health, a leading virtual clinic specializing in gastrointestinal (GI) conditions that delivers convenient, accessible, whole-person care through a collaborative, multidisciplinary approach. This partnership adds to Accolade's existing GI health partnership with Cylinder and reinforces Accolade's commitment to delivering best-in-class health solutions to customers and their employee and member populations.

    3/6/25 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    SEC Filings

    View All

    SEC Form 15-12G filed by Accolade Inc.

    15-12G - Accolade, Inc. (0001481646) (Filer)

    4/18/25 9:10:20 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13D/A filed by Accolade Inc.

    SCHEDULE 13D/A - Accolade, Inc. (0001481646) (Subject)

    4/10/25 9:03:06 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form 25-NSE filed by Accolade Inc.

    25-NSE - Accolade, Inc. (0001481646) (Subject)

    4/8/25 3:43:21 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/14/24 7:34:26 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Accolade Inc.

    SC 13G/A - Accolade, Inc. (0001481646) (Subject)

    11/12/24 12:26:15 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    SEC Form SC 13G filed by Accolade Inc.

    SC 13G - Accolade, Inc. (0001481646) (Subject)

    11/4/24 11:51:44 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Leadership Updates

    Live Leadership Updates

    View All

    Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction

    SAN FRANCISCO and SEATTLE, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, today announced the expiration of the waiting period under the Hart-Scott-Rodino ("HSR") Antitrust Improvements Act of 1976 with respect to the previously announced merger between the two companies. The transaction remains on track to be completed in the second quarter of calendar year 2025, subject to Accolade stockholder approval and satisfaction of other customary closing conditions. Glen Tullman, Chief Executive Officer of Transcarent, said, "With this milestone behind us, we ar

    2/24/25 5:20:27 PM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Expands Physician-Executive Leadership to Enhance Care Delivery and Improve the Healthcare Experience

    Welcomes Dr. Connie Hwang as chief medical officer, creates roles of chief health officer and chief nursing officer SEATTLE, Sept. 18, 2023 /PRNewswire/ -- Accolade (NASDAQ:ACCD) announced the expansion of its care delivery team, strengthening the company's ability to streamline healthcare experiences through physician-led advocacy. Connie Hwang, MD, MPH, joins Accolade to lead population health strategies for employers and health plans. Led by Shantanu Nundy, MD, executive vice president, chief health officer, the care delivery leadership team includes Dr. Hwang, senior vice president, chief medical officer; James Wantuck, MD, senior vice president, associate chief medical officer and co-fo

    9/18/23 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade appoints new chief information security officer

    With the addition of senior vice president and CISO, Kelli Burns, Accolade further elevates its focus on trusted, personalized relationships through exceptional information security for its members and customers SEATTLE, July 25, 2022 /PRNewswire/ -- Accolade, Inc. (NASDAQ:ACCD), the company that provides millions of people and their families with Personalized Healthcare, announced today that Kelli Burns has joined the organization as senior vice president, chief information security officer. Burns, a former consultant with Ernst & Young LLP (EY US) focused on cybersecurity en

    7/25/22 9:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    $ACCD
    Financials

    Live finance-specific insights

    View All

    Transcarent To Acquire Accolade

    Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment Transcarent's Generative AI WayFinding and care experiences combined with Accolade's Advocacy, Expert Medical Opinion, and Primary Care will deliver on the promise of ‘One Place for Health and Care' Accolade shareholders to receive $7.03 per share in cash SAN FRANCISCO and SEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Transcarent, the One Place for Health and Care, and Accolade (NASDAQ:ACCD), a leader in health advocacy, expert medical opinions, and primary care, announced that they have entered into a definitive agreement under which Transcarent wil

    1/8/25 8:30:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade to Announce Fiscal Third Quarter 2025 Financial Results

    SEATTLE, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced that it will release fiscal third quarter 2025 financial results on Thursday, January 9, 2024 after the market closes. In conjunction, the company will host a conference call to review results at 4:30 p.m. E.T. on the same day. Conference Call Details To Listen via Telephone: Pre-registration is required by the conference call operator. Please pre-register by clicking here. (https://register.vevent.com/register/BI0dce2f02ed2f44c8901127623aa788c3) Upon registering, you will be emailed a dial-in number, direct passcode and unique PIN. To Listen via Internet: The conference call can be accessed via a li

    12/16/24 8:00:00 AM ET
    $ACCD
    Business Services
    Consumer Discretionary

    Accolade Announces Results for Fiscal Second Quarter 2025

    SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ:ACCD) today announced financial results for the fiscal second quarter ended August 31, 2024. "As we enter the second half of fiscal year 2025, we are well positioned to deliver our first full year of Adjusted EBITDA profitability and positive cash flow. Accolade is proving the scalability and profitability of a business model and strategy that is fundamentally designed to improve the lives of millions of people and their families. Our focus remains on solving the Physician Gap through a physician-led advocacy approach that engages the entire healthcare ecosystem and enables a better healthcare experience for our members," s

    10/8/24 7:00:29 AM ET
    $ACCD
    Business Services
    Consumer Discretionary